{"id":851936,"date":"2025-05-16T10:56:10","date_gmt":"2025-05-16T14:56:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/"},"modified":"2025-05-16T10:56:10","modified_gmt":"2025-05-16T14:56:10","slug":"coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/","title":{"rendered":"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference"},"content":{"rendered":"

<\/p>\n

Coya Therapeutics to Participate at the H.C. Wainwright 3rd<\/sup> Annual BioConnect Investor Conference<\/b><\/p>\n

HOUSTON–(BUSINESS WIRE<\/a>)–Coya Therapeutics, Inc.<\/a> (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd<\/sup> Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025.\n<\/p>\n

\nChief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event.\n<\/p>\n\n\n\n\n\n\n
\n

Event:<\/b><\/p>\n<\/td>\n

\n

\nH. C. Wainwright 3rd<\/sup> Annual BioConnect Investor Conference\n<\/p>\n<\/td>\n<\/tr>\n

\n

Date:<\/b><\/p>\n<\/td>\n

\n

\nMay 20, 2025\n<\/p>\n<\/td>\n<\/tr>\n

\n

Time:<\/b><\/p>\n<\/td>\n

\n

\n12:30pm ET\n<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\n

\nNasdaq World Headquarters (151 West 43rd Street)\n<\/p>\n<\/td>\n<\/tr>\n

\n

Webcast:<\/b><\/p>\n<\/td>\n

\n

https:\/\/journey.ct.events\/view\/747c4fa8-f68f-4ff8-bc19-e40eb9c29759<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nTo schedule a one-on-one meeting with management, please contact meetings@hcwco.com.<\/a><\/p>\n

\nThe live and archived webcast will be accessible from the Company\u2019s website at https:\/\/coyatherapeutics.com\/<\/a> under the Investor Relations section – Events and Presentations. The replay of the webcast will be accessible for 90 days.\n<\/p>\n

About Coya Therapeutics, Inc.
\n
<\/b>Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (\u201cTregs\u201d) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.\n<\/p>\n

\nCoya\u2019s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya\u2019s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.\n<\/p>\n

\nCOYA 302 \u2013 the Company\u2019s lead biologic investigational product or “Pipeline in a Product” \u2013 is a proprietary combination of COYA 301 (Coya\u2019s proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson\u2019s Disease, and Alzheimer\u2019s Disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained and durable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.\n<\/p>\n

\nFor more information about Coya, please visit www.coyatherapeutics.com<\/a>.\n<\/p>\n

Forward-Looking Statements
\n
<\/b>This press release contains \u201cforward-looking\u201d statements that are based on our management\u2019s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d and similar expressions are intended to identify forward-looking statements.\n<\/p>\n

\nForward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.\n<\/p>\n

\nWe have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or will occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250516024813\/en\/<\/a><\/span><\/p>\n

Investor Contact
\n
<\/span><\/b>David Snyder, CFO
\n
david@coyatherapeutics.com
\n<\/a><\/p>\n

CORE IR
\n
<\/b>Bret Shapiro
\n
brets@coreir.com
\n<\/a>
561-479-8566<\/p>\n

Media Contacts
\n
<\/span><\/b>For Coya Therapeutics:
\n
<\/i>Kati Waldenburg
\n
media@coyatherapeutics.com
\n<\/a>
212-655-0924\n<\/p>\n

KEYWORDS:<\/b> United States North America Texas New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event. Event: H. C. Wainwright 3rd Annual BioConnect Investor Conference Date: May 20, 2025 Time: 12:30pm ET Location: Nasdaq World Headquarters (151 West 43rd Street) Webcast: https:\/\/journey.ct.events\/view\/747c4fa8-f68f-4ff8-bc19-e40eb9c29759 To schedule a one-on-one meeting with management, please contact meetings@hcwco.com. The live … <\/p>\n

Continue reading “Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-851936","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCoya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event. Event: H. C. Wainwright 3rd Annual BioConnect Investor Conference Date: May 20, 2025 Time: 12:30pm ET Location: Nasdaq World Headquarters (151 West 43rd Street) Webcast: https:\/\/journey.ct.events\/view\/747c4fa8-f68f-4ff8-bc19-e40eb9c29759 To schedule a one-on-one meeting with management, please contact meetings@hcwco.com. The live … Continue reading "Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-16T14:56:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference\",\"datePublished\":\"2025-05-16T14:56:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/\"},\"wordCount\":1091,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/\",\"name\":\"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-05-16T14:56:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Market Newsdesk","og_description":"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event. Event: H. C. Wainwright 3rd Annual BioConnect Investor Conference Date: May 20, 2025 Time: 12:30pm ET Location: Nasdaq World Headquarters (151 West 43rd Street) Webcast: https:\/\/journey.ct.events\/view\/747c4fa8-f68f-4ff8-bc19-e40eb9c29759 To schedule a one-on-one meeting with management, please contact meetings@hcwco.com. The live … Continue reading \"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-16T14:56:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference","datePublished":"2025-05-16T14:56:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/"},"wordCount":1091,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/","name":"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-05-16T14:56:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250516024813r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=851936"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851936\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=851936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=851936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=851936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}